AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33393445
Drug: Lactulose 2
RxNorm normalized name: lactulose 2500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose 2 g/day for 2 weeks
Trial: 35481712
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg daily for 3 months
Trial: 35481712
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional treatment (warfarin or rivaroxaban)
Trial: 32807659
Drug: Hydrogel lenses
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel lenses in combination with silver cases
Trial: 36216624
Drug: Extraction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction treatment (4 first premolars removed)
Trial: 36216624
Drug: Nonextraction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextraction treatment
Trial: 36216624
Drug: Extraction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction treatment with minimal lip strain
Trial: 32631388
Drug: AHE (Allium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHE (Allium hookeri extract) 486 mg/day
Trial: 39229471
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants
Trial: 36318499
Drug: Narrative writing
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative writing intervention with resources and support from a narrative medicine facilitator
Trial: 34731574
Drug: Conversation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversation group treatment (1 hr, twice per week, for 10 weeks)
Trial: 32147071
Drug: Topical henna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical henna preparation applied every night for two weeks
Trial: 36315457
Drug: Medical-grade honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical-grade honey (MGH) applied intra-socket (L-Mesitran Soft)
Trial: 32501985
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban (20 μg/kg)
Trial: 32501985
Drug: Medium-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose tirofiban (10 μg/kg)
Trial: 36006034
Drug: Gabapentin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (100 mg)
Trial: 36006034
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg lactose powder)
Trial: 33160854
Drug: Tα1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tα1 treatment (1.6 mg subcutaneous injection for 15 days)
Trial: 33160854
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (untreated, regular supportive treatment)
Trial: 35022730
Drug: Ceftolozane/tazobactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam (3 g, 2 g ceftolozane/1 g tazobactam q8h)
Trial: 35022730
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g q8h)
Trial: 35231769
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg EO-PGS
Trial: 35231769
Drug: 0.75 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g/kg EO-PGS
Trial: 32207659
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy defibrillators (CRT-D)
Trial: 35254752
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA) with fluocinolone-based triple cream
Trial: 34806244
Drug: Party and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Party and play use (methamphetamine, gamma-hydroxybutyrate, amyl nitrites, erectile dysfunction drugs)
Trial: 32419092
Drug: Total effective
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total effective dose (FDT)
Trial: 32419092
Drug: Total effective
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total effective dose (ABT)
Trial: 32419092
Drug: Total effective
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total effective dose (MBT)
Trial: 32419092
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of total effective doses among groups A, B, and C
Trial: 36397128
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg/daily)
Trial: 32067401
Drug: No Oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Oral Appliance (no OA)
Trial: 36695874
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group A (TAD/HAM versus HAM/HAM ± G‐CSF followed by TAD and maintenance)
Trial: 36695874
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group B (intermediate‐dose ara‐C/mitoxantrone followed by ara‐C/mitoxantrone)
Trial: 33611761
Drug: High-dose methotrexate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate-based chemotherapy with rituximab
Trial: 39612621
Drug: (Neo)adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Neo)adjuvant chemotherapy
Trial: 35010917
Drug: CIT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIT plus BR (3 g/kg/day of CIT plus 3 mg/kg/day of nitrates)
Trial: 35010917
Drug: CIT (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIT (3 g/kg/day)
Trial: 35010917
Drug: BR (3
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BR (3 mg/kg/day of NO3‐)
Trial: 36045183
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy using an 830-nm LED device
Trial: 33588594
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 or 110 mg BID)
Trial: 33588594
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg QD)
Trial: 33017580
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms will provide step-up therapy of open-label amlodipine 5 mg if blood pressure is >140/90 at 6 weeks
Trial: 32374030
Drug: FDC-2 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC-2 (10 mg macitentan/40 mg tadalafil)
Trial: 35511451
Drug: Pressure-controlled ventilation-volume
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-controlled ventilation-volume guaranteed (PCV-VG) with tidal volume set to 6 ml/kg and PEEP at 7 cm H2O
Trial: 35511451
Drug: Volume controlled
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume controlled ventilation (VCV) with tidal volume set to 8 ml/kg
Trial: 32965478
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable antipsychotics
Trial: 37267732
Drug: Omega-3 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplements
Trial: 34438354
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2000 mg/day
Trial: 36250938
Drug: Intravesical mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin-C (IMMC) 40 mg/20 mL, administered 1 day and 4 hours before TURBT
Trial: 37441145
Drug: Intradermal acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal acupuncture (IA) treatment
Trial: 35773113
Drug: Sedative use
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative use (pretreatment)
Trial: 35773113
Drug: Cocaine use
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine use (initial 4 weeks of treatment)
Trial: 35773113
Drug: Sedative use
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative use (initial 4 weeks of treatment)
Trial: 34144282
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g EP/calf per day (ECL)
Trial: 34144282
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g EP/calf per day (ECH)
Trial: 34593565
Drug: Rucaparib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib monotherapy (600 mg orally twice a day)
Trial: 34294036
Drug: Multimodal comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal comprehensive care methodology training programme for family caregivers (6 hours total, three sessions of 2 hours each over 3 months, followed by weekly information delivery via postcard)
Trial: 35559992
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of azithromycin (standard of care)
Trial: 33961145
Drug: Renin-angiotensin blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin blockers
Trial: 33062063
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab
Trial: 36031718
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg ethanol
Trial: 35255832
Drug: COLM-SST (caraway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COLM-SST (caraway oil and L-menthol)
Trial: 32121000
Drug: Unadjusted Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unadjusted Hb cut-off <12 g/dL
Trial: 33497295
Drug: Perineural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural bupivacaine infiltration (2 mL of 0.5% bupivacaine)
Trial: 34633992
Drug: 0.5 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg·kg‐1 ketamine for 40 minutes
Trial: 33677450
Drug: Azilsartan 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 20 mg daily for 3 months
Trial: 33677450
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg daily for 3 months
Trial: 35068500
Drug: Bepotastine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepotastine 10 mg tablet twice daily
Trial: 35068500
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg tablet once daily
Trial: 36203797
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (two capsules containing multi-strain probiotics daily)
Trial: 35381194
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (<100 mmol or <1500 mg/day)
Trial: 32740079
Drug: High-volume split-dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume split-dose PEG (2 L + 2 L)
Trial: 34509641
Drug: Low-volume split-dose
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume split-dose PEG (1 L + 1 L) + bisacodyl (15 mg)
Trial: 34036357
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g cheddar cheese
Trial: 33476537
Drug: Total glucosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glucosides of paeony (TGP) treatment group
Trial: 32812478
Drug: Pain neuroscience
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain neuroscience education (PNE), manual therapy (MT), and home exercise program (HEP)
Trial: 32812478
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT) and home exercise program (HEP)
Trial: 34362762
Drug: Automatic oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic oxygen titration using a novel nasal high-flow device
Trial: 34362762
Drug: Manual oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual oxygen titration using nasal high flow
Trial: 34362762
Drug: Automatic oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic oxygen titration
Trial: 32539853
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of pan-genotypic DAA treatment with individualized follow-up
Trial: 39104653
Drug: Abrocitinib 200
RxNorm normalized name: abrocitinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib 200 mg
Trial: 33859330
Drug: Galacto-oligosaccharides (GOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto-oligosaccharides (GOS) prebiotic supplement
Trial: 32341247
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment at 20 mm Hg
Trial: 36267207
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg)
Trial: 33956130
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg biweekly)
Trial: 33956130
Drug: Nivolumab (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (fixed dose of 240 mg biweekly or 480 mg monthly)
Trial: 33243815
Drug: CAP256V2LS administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP256V2LS administered intravenously
Trial: 33243815
Drug: CAP256V2LS+PGT121 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP256V2LS+PGT121 administered SC
Trial: 33243815
Drug: CAP256V2LS+VRC07-523LS+PGT121 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP256V2LS+VRC07-523LS+PGT121 administered SC
Trial: 34058717
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (7000 mg/d)
Trial: 34058717
Drug: Medium sodium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium sodium diet (2300 mg/d)
Trial: 34058717
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (1000 mg/d)
Trial: 35543540
Drug: 20 intradetrusor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 intradetrusor injections of onabotulinumtoxinA
Trial: 32950829
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (30–50 mg·kg−1 intravenously as a bolus before induction, followed by 10–20 mg·kg−1 h−1 continuous infusion during surgery)
Trial: 616351330
Drug: Liquid L‐T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid L‐T4 formulation
Trial: 616351330
Drug: Tablet form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet form L‐T4
Trial: 33607177
Drug: Baricitinib (Jak1/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (Jak1/2 inhibitor), oral treatment for four weeks
Trial: 36303868
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of white common bean extract (WCBE) taken half an hour before a meal (Group W)
Trial: 36303868
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of maltodextrin as a placebo (Group C)
Trial: 36303868
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of white common bean extract (WCBE) (Group W)
Trial: 35068061
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + tamsulosin 0.4 mg once daily
Trial: 34691317
Drug: Moxibustion plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion plus routine drug therapy
Trial: 34041702
Drug: Upadacitinib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 7.5 mg
Trial: 36498228
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 6 weeks
Trial: 36498228
Drug: 770 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 770 mg/day of Tribulus terrestris L. (TT) for 6 weeks
Trial: 36241249
Drug: Adjunctive plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive plasma exchange therapy
Trial: 36241249
Drug: Intensive immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive immunosuppressive therapy
Trial: 35631229
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (100 mg oral daily for 1 month)
Trial: 32760093
Drug: Peribulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar anesthesia with 4 6 ml of 1% ropivacaine
Trial: 35843923
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg tablet (test product)
Trial: 35843923
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg tablet (reference product)
Trial: 33465818
Drug: Regular daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular daily intake of PPIs
Trial: 32352714
Drug: Open-label rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label rifaximin 550 mg 3 times daily for 2 weeks
Trial: 32352714
Drug: Double-blind rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind rifaximin 550 mg 3 times daily
Trial: 33979219
Drug: Low-frequency contact
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency contact ultrasonic debridement therapy (LFCUD) alone
Trial: 616576545
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + sitagliptin (100 mg once daily)
Trial: 35565077
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement therapy assisted using Bioptron Hyperlight Therapy
Trial: 35565077
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement therapy alone
Trial: 32595055
Drug: IV Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Lidocaine (5 cc = 100 mg)
Trial: 32595055
Drug: IV Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Morphine sulfate (5 cc = 5 mg)
Trial: 36380383
Drug: Real Time
RxNorm normalized name: MENTHOL 15 mg in 1 g TOPICAL CREAM [Real Time Pain Relief Foot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real Time Medication Monitoring (RTMM)
Trial: 36380383
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of self-report and pharmacy refill count
Trial: 36380383
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three measures (self-report, pharmacy refill count, RTMM)
Trial: 32567217
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (3 mg/mL)
Trial: 32567217
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (1 mg/mL)
Trial: 33337391
Drug: Dexamethasone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.75 mg/kg/day for 6 days)
Trial: 39256427
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB)
Trial: 34904270
Drug: Linzagolix 25–200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linzagolix 25–200 mg daily
Trial: 33368499
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg/day
Trial: 32064621
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus β‐D mannuronic acid (M2000)
Trial: 39762953
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (control)
Trial: 36244652
Drug: High-dose losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose losartan (150 mg/day)
Trial: 32735145
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg etanercept
Trial: 32735145
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg etanercept